An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes

用于 1 型糖尿病早期诊断和改进治疗的超灵敏、高通量和低成本自身免疫组合

基本信息

  • 批准号:
    9559575
  • 负责人:
  • 金额:
    $ 74.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-08-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

Type 1 diabetes (T1D) is a devastating autoimmune disease that destroys islet-cell insulin production. Millions of Americans, especially children, are affected and must rely on lifelong insulin administration and struggle with life-threatening co-morbidities. Most new cases of T1D are diagnosed in emergency settings with presentation in potentially deadly diabetic ketoacidosis (DKA). Current pre-clinical diagnostic tests that can permit preventive action for T1D are slow and not readily available outside of tertiary care centers. In this proposal Enable Biosciences will further develop and validate a novel low-cost and high-throughput immunoassay to rapidly and sensitively screen for the four cardinal autoantibody markers that predict risk for type 1 diabetes. Such a test could supplant the current expensive, slow radioactive method. By reducing costs while retaining sensitivity and specificity with a robust very low-sample volume assay, Enable Biosciences' product will permit increased testing to reveal incipient T1D in the general population at the optimal time for intervention. During the Phase I funding period, Enable prototyped a 3-member T1D autoantibody panel using their core Antibody Detection by Agglutination-PCR (ADAP) technology and demonstrated substantial equivalence with the gold-standard assay while removing reliance on radioactive reagents. In this Phase 2 proposal, Enable presents a comprehensive plan to enhance this panel via automation using a dedicated robotic liquid handling system, greatly increasing assay throughput and reliability while further reducing costs. We will also adapt our assay chemistry to be able to use Taqman probes. This will result in further throughput acceleration and cost reductions. Building upon promising preliminary results from Phase 1 work, we will incorporate the fourth and final T1D autoantibody (ZnT8) to create the world's first ever “4-in-1” screening panel, creating a product that provides the highest level of risk assessment for T1D screening and diagnosis. These optimized and automated panels will then be rigorously validated with thousands of clinical samples provided by our wide network of enthusiastic academic and institutional partners that include the Joslin Diabetes Center, Stanford School of Medicine, the T1D Exchange and Tufts Children's Hospital. This data will be used to plan and direct commercialization efforts that will include a phased approach from delivering a CLIA-certified laboratory service to FDA-approved reagent kits with companion integrated sample-to-answer hardware devices for easy, low-skill use and deployment across research and clinical laboratories and screening sites worldwide.
1型糖尿病(T1 D)是一种破坏胰岛细胞胰岛素产生的破坏性自身免疫性疾病。数以百万计的美国人,特别是儿童,受到影响,必须依靠终身胰岛素管理和与危及生命的合并症作斗争。大多数新发T1 D病例是在紧急情况下诊断的,表现为潜在致命的糖尿病酮症酸中毒(DKA)。目前的临床前诊断测试,可以允许T1 D的预防措施是缓慢的,并不容易获得三级保健中心以外。在这项提案中,Enable Biosciences将进一步开发和验证一种新型的低成本和高通量免疫测定法,以快速灵敏地筛选预测1型糖尿病风险的四种主要自身抗体标志物。这样的测试可以取代目前昂贵的,缓慢的放射性方法。通过降低成本,同时保持灵敏度和特异性与一个强大的非常低的样本量测定,启用生物科学公司的产品将允许增加测试,以揭示早期T1 D在一般人群中的最佳干预时间。在I期资助期间,Enable使用其核心抗体检测-聚合酶链反应(ADAP)技术制作了3人T1 D自身抗体样本组原型,并证明了与金标准检测试剂盒的实质等同性,同时消除了对放射性试剂的依赖。在第二阶段提案中,Enable提出了一项全面的计划,通过使用专用机器人液体处理系统的自动化来增强该面板,大大提高了分析吞吐量和可靠性,同时进一步降低了成本。我们还将调整我们的测定化学,以便能够使用Taqman探针。这将导致进一步的吞吐量加速和成本降低。在第一阶段工作的初步结果的基础上,我们将结合第四种也是最后一种T1 D自身抗体(ZnT 8)来创建世界上第一个“4合1”筛查面板,创建一种为T1 D筛查和诊断提供最高水平风险评估的产品。这些优化和自动化的面板将通过我们广泛的学术和机构合作伙伴网络提供的数千份临床样本进行严格验证,这些合作伙伴包括Joslin糖尿病中心,斯坦福大学医学院,T1 D交换和塔夫茨儿童医院。这些数据将用于规划和指导商业化工作,包括从提供CLIA认证的实验室服务到FDA批准的试剂盒的分阶段方法,以及配套的集成样本到答案硬件设备,以便在全球研究和临床实验室以及筛查中心轻松,低技能使用和部署。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Seftel其他文献

David Seftel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Seftel', 18)}}的其他基金

Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk
开发自动化高通量干血斑测定法以促进大规模筛查 1 型糖尿病风险
  • 批准号:
    10020787
  • 财政年份:
    2019
  • 资助金额:
    $ 74.98万
  • 项目类别:
Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk
开发自动化高通量干血斑测定法以促进大规模筛查 1 型糖尿病风险
  • 批准号:
    9910015
  • 财政年份:
    2019
  • 资助金额:
    $ 74.98万
  • 项目类别:
Multiplex food allergy diagnostic based on IgE immunologic markers
基于 IgE 免疫标记物的多重食物过敏诊断
  • 批准号:
    10011621
  • 财政年份:
    2018
  • 资助金额:
    $ 74.98万
  • 项目类别:
Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance
利用自我收集的毛细血管干血点推进易于使用、高通量和多重胰岛自身抗体测试,以供监管审批
  • 批准号:
    10699934
  • 财政年份:
    2016
  • 资助金额:
    $ 74.98万
  • 项目类别:
Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring
凝集 PCR 抗体检测 (ADAP):一种用于 T1D 诊断和监测的超灵敏、高通量、可多重工具
  • 批准号:
    9185244
  • 财政年份:
    2016
  • 资助金额:
    $ 74.98万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 74.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了